Literature DB >> 17007735

Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.

Lin-hui Wang1, Zheng-hong Qin.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, which is caused by an abnormal expansion of Cytosine Adenine Guanine (CAG) trinucleotide repeat in the gene making huntingtin (Htt). Despite intensive research efforts devoted to investigate molecular mechanisms of pathogenesis, effective therapy for this devastating disease is still not available at present. The development of various animal models of HD has offered alternative approaches in the study of HD molecular pathology. Many HD models, including chemical-induced models and genetic models, mimic some aspects of HD symptoms and pathology. To date, however, there is no ideal model which replicates all of the essential features of neuropathology and progressive motor and cognitive impairments of human HD. As a result, our understanding of molecular mechanisms of pathogenesis in HD is still limited. A new model is needed in order to uncover the pathogenesis and to develop novel therapies for HD. In this review we discussed usefulness and limitations of various animal and cellular models of HD in uncovering molecular mechanisms of pathogenesis and developing novel therapies for HD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007735     DOI: 10.1111/j.1745-7254.2006.00410.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  8 in total

1.  Motor function and dopamine release measurements in transgenic Huntington's disease model rats.

Authors:  Andrea N Ortiz; Gregory L Osterhaus; Kelli Lauderdale; Luke Mahoney; Stephen C Fowler; Stephan von Hörsten; Olaf Riess; Michael A Johnson
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

2.  Original Research: Feasibility and safety of two surgical techniques for the development of an animal model of jugular vein occlusion.

Authors:  Luigi Auletta; Adelaide Greco; Sandra Albanese; Leonardo Meomartino; Marco Salvatore; Marcello Mancini
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-05

Review 3.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 4.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

Review 5.  Modeling mitochondrial dysfunctions in the brain: from mice to men.

Authors:  Megan E Breuer; Peter H G M Willems; Frans G M Russel; Werner J H Koopman; Jan A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2011-07-14       Impact factor: 4.982

6.  Restoration of the striatal circuitry: from developmental aspects toward clinical applications.

Authors:  Marie-Christin Pauly; Tobias Piroth; Máté Döbrössy; Guido Nikkhah
Journal:  Front Cell Neurosci       Date:  2012-04-19       Impact factor: 5.505

7.  A novel ex vivo Huntington's disease model for studying GABAergic neurons and cell grafts by laser microdissection.

Authors:  E M André; N Daviaud; L Sindji; J Cayon; R Perrot; C N Montero-Menei
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

Review 8.  3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future.

Authors:  Isaac Túnez; Inmaculada Tasset; Verónica Pérez-De La Cruz; Abel Santamaría
Journal:  Molecules       Date:  2010-02-10       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.